<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d12" origId="Cisplatin"><sentence id="DrugDDI.d12.s0" origId="s0" text="Plasma levels of anticonvulsant agents may become subtherapeutic during cisplatin therapy."><entity id="DrugDDI.d12.s0.e0" origId="s0.p1" charOffset="17-37" type="drug" text="anticonvulsant agent"/><entity id="DrugDDI.d12.s0.e1" origId="s0.p5" charOffset="72-81" type="drug" text="cisplatin"/><pair id="DrugDDI.d12.s0.p0" e1="DrugDDI.d12.s0.e0" e2="DrugDDI.d12.s0.e1" interaction="?"/></sentence><sentence id="DrugDDI.d12.s1" origId="s1" text="In a randomized trial in advanced ovarian cancer, response duration was adversely affected when pyridoxine was used in combination with altretamine (hexamethylmelamine) and cisplatin.1"><entity id="DrugDDI.d12.s1.e0" origId="s1.p13" charOffset="96-106" type="drug" text="pyridoxine"/><entity id="DrugDDI.d12.s1.e1" origId="s1.p17" charOffset="136-147" type="drug" text="altretamine"/><entity id="DrugDDI.d12.s1.e2" origId="s1.p19" charOffset="149-167" type="drug" text="hexamethylmelamine"/><entity id="DrugDDI.d12.s1.e3" origId="s1.p22" charOffset="173-182" type="drug" text="cisplatin"/><pair id="DrugDDI.d12.s1.p0" e1="DrugDDI.d12.s1.e0" e2="DrugDDI.d12.s1.e1" interaction="?"/><pair id="DrugDDI.d12.s1.p1" e1="DrugDDI.d12.s1.e0" e2="DrugDDI.d12.s1.e2" interaction="?"/><pair id="DrugDDI.d12.s1.p2" e1="DrugDDI.d12.s1.e0" e2="DrugDDI.d12.s1.e3" interaction="?"/><pair id="DrugDDI.d12.s1.p3" e1="DrugDDI.d12.s1.e1" e2="DrugDDI.d12.s1.e2" interaction="?"/><pair id="DrugDDI.d12.s1.p4" e1="DrugDDI.d12.s1.e1" e2="DrugDDI.d12.s1.e3" interaction="?"/><pair id="DrugDDI.d12.s1.p5" e1="DrugDDI.d12.s1.e2" e2="DrugDDI.d12.s1.e3" interaction="?"/></sentence></document>